Dual nanobody-redirected and Bi-specific CD13/TIM3 CAR T cells eliminate AML xenografts without toxicity to human HSCs., PMID:39976474
Development of chimeric antigen receptor T cells targeting cancer-expressing podocalyxin., PMID:39867135
Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL., PMID:39820359
A Switch Protein Adapter for Anti-LILRB4 CAR-T Cells., PMID:39663681
A novel bispecific T-cell engager using the ligand-target csGRP78 against acute myeloid leukemia., PMID:39196413
Development of novel humanized CD19/BAFFR bicistronic chimeric antigen receptor T cells with potent antitumor activity against B-cell lineage neoplasms., PMID:38960449
S309-CAR-NK cells bind the Omicron variants in vitro and reduce SARS-CoV-2 viral loads in humanized ACE2-NSG mice., PMID:38767356
Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22., PMID:38596311
Characterization of novel CD19-specific VHHs isolated from a camelid immune library by phage display., PMID:38066569
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study., PMID:38066564
Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells., PMID:37965326
An antibody fragment-decorated liposomal conjugate targets Philadelphia-like acute lymphoblastic leukemia., PMID:37898250
Enhanced tumor immunotherapy by polyfunctional CD19-CAR T cells engineered to secrete anti-CD47 single-chain variable fragment., PMID:37781520
A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models., PMID:37740214
CAR T-Cell Therapy for Cancer: Latest Updates and Challenges, with a Focus on B-Lymphoid Malignancies and Selected Solid Tumours., PMID:37371056
A simplified function-first method for the discovery and optimization of bispecific immune engaging antibodies., PMID:37347762
T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts., PMID:36875091
Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy., PMID:36851890
Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma., PMID:36681817
A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2+ Solid Cancer., PMID:36672182
Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition., PMID:36435066
Liposomal T cell engager and re-director for tumor cell eradication in cancer immunotherapy., PMID:36041060
A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL., PMID:35981465
[Optimization of CD19 chimeric antigen receptor T cell establishment and observation of the killing effect in vitro and in vivo]., PMID:35968595
NK Cells Equipped With a Chimeric Antigen Receptor That Overcomes Inhibition by HLA Class I for Adoptive Transfer of CAR-NK Cells., PMID:35585985
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy., PMID:35410148
Assessing the Future of Solid Tumor Immunotherapy., PMID:35327456
A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL., PMID:35288466
Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation., PMID:35222427
Site-Specific Dinitrophenylation of Single-Chain Antibody Fragments for Redirecting a Universal CAR-T Cell against Cancer Antigens., PMID:35218770
Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia., PMID:35179242
Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains., PMID:35117999
Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy., PMID:34966954
A Targeted Catalytic Nanobody (T-CAN) with Asparaginolytic Activity., PMID:34830793
TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma., PMID:34445415
Incorporation of a Novel CD16-Specific Single-Domain Antibody into Multispecific Natural Killer Cell Engagers With Potent ADCC., PMID:33999642
Development and functional characterization of novel fully human anti-CD19 chimeric antigen receptors for T-cell therapy., PMID:33432627
Case Report: Humanized Selective CD19CAR-T Treatment Induces MRD-Negative Remission in a Pediatric B-ALL Patient With Primary Resistance to Murine-Based CD19CAR-T Therapy., PMID:33424835
GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma - assessing tumor and T cell interaction., PMID:33321428
Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line., PMID:33271901
Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies., PMID:33239418
Production of a novel bispecific protein ULBP1×CD19-scFv targeting the NKG2D receptor and CD19 to promote the activation of NK cells., PMID:33122138
Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy., PMID:33023981
Adaptable antibody Nanoworms designed for non-Hodgkin lymphoma., PMID:32916604
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia., PMID:32894185
Driving CARs with alternative navigation tools - the potential of engineered binding scaffolds., PMID:32794303
Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope., PMID:32788237
Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides., PMID:32541028
Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study., PMID:32449004
Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma., PMID:32435496
For research use only. Not for human or drug use.
